info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
us US: +18317045538    uk UK: +441256636046    in IN: +918260836500
Home » Healthcare » Cancer Monoclonal Antibodies Market Size, Global Report, 2030

Cancer Monoclonal Antibodies Market By Antibody Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Others), By Medication Type (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Pertuzumab (Perjeta), Others), By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others), By End-User (Hospitals and Clinics, Pharmacies, Research Laboratories, Others), By Geography, Size, Share, Growth, Global Industry Report, Industry Forecast, 2021-2030

Published On: Jul-2022   |   Base Year: 2021   |   No Of Pages: 135   |   Historical Data: 2015 - 2019   |   Formats: PDF   |   Report ID: 42337305

Report DescriptionTable of Contents

The global cancer monoclonal antibodies market size was $51.88 billion in 2021 and is predicted to reach $108.47 billion by 2030, at a CAGR of 8.54% throughout the forecasted period of 2021-2030.

 

The Monoclonal antibodies are the laboratory made antibodies that are assigned to certain targets in the body of the Homo Sapiens. They act as antigens on the surface of the carcinogenic cells. There are a plethora of monoclonal antibodies & each antibody is prepared in such a way that it binds to only one type of antigen. These antibodies are widely used for the treatment of a variety of diseases along with certain types of cancers. They carry the injected drugs or radioactive substances directly to the cancer cells. A research survey revealed that cancer treatment using radioactive substances is the most common form of cancer therapy in the world. Nearly 50% of the patients suffering from cancer undergo radiation therapy & it contributes approximately 40% of the curative treatment of cancer.

 

The combination of the radioactive substances with chemotherapy drugs are known as Conjugated Monoclonal Antibodies. These antibodies are also widely employed in the cancer treatment. They are a sort of targeted cancer treatment that interacts with specific targets. Certain monoclonal antibodies are also used as immunotherapy because they help to build the immune system against cancer. According to GLOBOCAN 2020 figures, an estimated 19,292,789 people will be diagnosed with cancer in 2020. According to the same source cited above, cancer patients are expected to reach 30.2 million by 2040.

 

Cancer Monoclonal Antibodies Market Infographic 2020-2030

 

Market Dynamics: -

Key Market Drivers: - (Increasing cancer prevalence, Increasing demand for the specificity of monoclonal antibodies in order to target cancer, Increasing focus on R&D in cancer serology)

  • Cancer is affecting an increasing number of individuals throughout the world. According to the World Health Organization's (WHO) February 2022 estimate, Cancer will claim the lives of around 10 million people globally in 2020. Prostate, lung, bowel, and female breast cancer are the four most frequent kinds of Cancer globally, accounting for 44 per cent of all new cases of cancer.

 

  • According to the paper "Monoclonal antibodies and Cancer Treatment: What to Know," released in November 2020, Cancer isn't the only condition treated with monoclonal antibodies. The coronavirus has also been discovered as an antibody target. By inhibiting infected cells from being proliferated, monoclonal antibodies assist in decreasing the duration of severe sickness. Due to the increased usage of monoclonal antibodies in COVID-19, the cancer monoclonal antibodies market analysed was severely influenced.

 

  • Monoclonal antibodies market growth potential will be boosted by a strong focus on researching and developing naked monoclonal antibody therapies to provide highly targeted drug therapy for complicated and severe illnesses. Companies would profit greatly from government backing and regulatory permissions to build the monoclonal antibody business. For instance, According to Bristol Myers Squibb, in 2021, The European Commission (EC) authorised Bristol Myers Squibb's OPDIVO and Yervoy combination medication to treat hematologic malignancies in pleural mesothelioma patients. As a result, the product line's availability in the market will be extended.

 

Restraints: - (Huge cost associated in the making of Monoclonal antibodies)

  • Due to the complicated production process, clinical studies, expensive biological and chemical components,  and mandatory safety, testing, effectiveness, and quality checks, the high costs associated with developing monoclonal antibodies using modern techniques operate as a key restraint for the market. Large-scale manufacturing of monoclonal antibodies involving numerous and post-translational modifications that needs advanced equipment, which is costly and disulfide bonds. Clinical effectiveness is often obtained by injecting huge doses of monoclonal antibodies in the system, which necessitates the production of large quantities for each therapy, raising the cost. According to AJMC (American Journal of Managed Care), monoclonal antibody medicines for oncology and haematology cost roughly $100,000 more per year than those for other diseases. As a result, the market expansion will be limited by the huge development costs of these new approaches.

 

Opportunities: - (Increasing consumption of Tobacco, Rise of government initiatives)

  • According to the WHO (World Health Organization), in February 2022, tobacco smoking, a high body mass index, a low fruit and vegetable diet, alcohol consumption and a lack of physical exercise account for around one-third of cancer fatalities. As a result, rising tobacco usage is predicted to lead to an increase in cancer prevalence, boosting the industry growth.

 

  • The rise of cancer cases all across the world have compelled the governments worldwide to invest a hefty amount in the laboratories in order to manufacture the highly efficient monoclonal antibodies for cancer treatment. Moreover, the governments have also increased their rate of approval for the monoclonal antibodies which in turn can cater to a plethora of opportunities for the market in the years to come. SMR conducted a thorough research study where it was revealed that till date, the U.S. FDA have approved more than 100 monoclonal antibodies for the treatment of various types of cancers.

 

Global Cancer Monoclonal Antibodies Market Share 2020-2030

 

Global Cancer Monoclonal Antibodies Market Different Segments Analysis

The Segmentation of the is based on Medication Type, End-User and Region.

Based on the Medication Type

  • Bevacizumab (Avastin)

  • Rituximab (Mabthera)

  • Pertuzumab (Perjeta)

  • Panitumumab (Vectibix)

  • Cetuximab (Erbitux)

  • Trastuzumab (Herceptin)

  • Others

 

Based on End-User

  • Hospitals and Clinics

  • Pharmacies

  • Research Laboratories

  • Others

 

By Antibody Type

  • Murine Antibodies

  • Chimeric Antibodies

  • Humanized Antibodies

  • Others

 

By Application

  • Breast Cancer

  • Blood Cancer

  • Liver Cancer

  • Brain Cancer

  • Colorectal Cancer

  • Others

 

Based on Regions

North America

  • The U.S.

  • Canada

  • Mexico

  • Rest of North America

 

Europe

  • France

  • Germany

  • U.K

  • Spain

  • Italy

  • Rest of Europe

 

Asia Pacific

  • India   

  • China

  • Japan

  • Australia

  • Rest of APAC

 

LAMEA

  • Brazil

  • South Africa

  • Saudi Arabia

  • Rest of LAMEA

 

Cancer Monoclonal Antibodies Market End-user 2020-2030

 

Based on Medication Type, Trastuzumab (Herceptin) held the largest cancer monoclonal antibodies market share in 2020. It's also the first-line therapy for HER2-positive metastatic stomach or gastro-oesophageal junction cancer. Because of the prolonged length of therapy in conjunction with Perjeta, the market has continued to expand. The increased global prevalence of Cancer will boost the segment's expansion. As asserted by World Health Organization (WHO), 2.3 million women were diagnosed and detected with breast cancer in 2020, with 685,000 deaths worldwide. Breast cancer has been diagnosed in 7.8 million women in the previous five years ending in 2020, making it the most common disease in the world. As a result, the increasing frequency of rapidly spreading breast cancer will increase the overall demand for Herceptin monoclonal antibodies, which will lead the industry growth.

 

In the End-User segment, Hospitals held the maximum share due to a rise in the number of patients admitted to hospitals for various chronic illnesses. Patient preference has been influenced by the availability of modern medication therapy in institutions. Highly skilled professionals providing specialized treatments for diseases such as autoimmune diseases and cancer will drive the demand of the product in hospitals. On top of that, better reimbursement policies for high-cost therapies prevailing in hospitals will influence patient visits.

 

In the Regions segment, North America held the maximum share. Biotechnology and Pharmaceutical companies have a wealth of experience and understanding in cancer monoclonal antibodies. According to the American Cancer Society's 2022 projections, roughly 235,000 new  lung cancer cases will be detected in the United States in 2022. According to the same source, around 79,000  instances of kidney cancer would be diagnosed in 2022, with 13,800 fatalities. The increased prevalence of cancer is predicted to increase demand for the ablation devices, resulting in market expansion.  

 

Report Attribute

Details

Forecast Period

2021 - 2030

Market size value in 2021

USD 51.88 Billion

Revenue forecast in 2030

USD 108.47 Billion

Growth rate

CAGR of approximately 8.54%

Base year for estimation

2021

Unit

USD Billion, CAGR (2021 - 2030)

Segmentation

By Solutions, By Deployment, By Region

By Medication Type

Rituximab (Rituxan), Bevacizumab (Avastin), Cetuximab (Erbitux), Panitumumab (Vectibix), Trastuzumab (Herceptin), and Others

By End-User

Hospitals and Clinics, Research Laboratories, Others

By Region

Asia Pacific, North America, Europe, LAMEA

Country Scope

U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc.

Company Usability Profiles

Bristol Myers Squibb Company, Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche AG, Genmab AS, Amgen Inc., GlaxoSmithKline PLC, Eli Lilly and Company, Seattle Genetics Inc., and Spectrum Pharmaceuticals Inc., among others, hold the substantial market share in the market studied.

 

Global Cancer Monoclonal Antibodies Market Competitive Landscape Analysis

The competitive landscape analysis entails information pertaining to the global competitors who are operating in the dynamic marketplace. The comparison is performed based on initiatives, company overview, investment in R&D, company financials, overall revenue generation, company strengths and weaknesses, global presence, SWOT Analysis, production capacity, PESTLE Analysis, production sites and facilities, potential, etc.

 

The key players that are included in the industry Analysis are:

  • Johnson & Johnson

  • Novartis AG

  • Eli Lilly and Company

  • F. Hoffmann-La Roche AG

  • Seattle Genetics Inc.

  • GlaxoSmithKline PLC

  • Amgen Inc.

  • Bristol Myers Squibb Company

  • Genmab AS

  • Spectrum Pharmaceuticals Inc.

 

Cancer Monoclonal Antibodies Market region 2020-2030

 

Recent Developments

  • On July 6th 2022, Next Cure announced the development of a highly effective Immunohistochemical assay for further laboratory investigations on the monoclonal antibodies. This IHC (immunohistochemical) assay was manufactured with the combination of S15 Monoclonal Antibody that detects a unique & rare cytoplasmic domain of the respective protein.

 

  • On July 6th 2022, Junshi Biosciences & Coherus announced that the FDA has successfully approved the resubmission of Toripalimab for the treatment of Nasopharyngeal Cancer. Toripalimab is regarded as an anti PD 1 Monoclonal antibody that is developed for the purpose of blocking the PD-1 interactions with its respective ligands.

 

  • On July 5th 2022, AstraZeneca announced that it is planning to acquire TeneoTwo of worth USD 100 million. It is by far the largest deal made by a pharmaceutical company for developing a new type of targeted cancer therapy known as T Cell Engager. Moreover, it also declared that the phase 1 testing of a drug called TNB-486 is already in the process. If this drug achieves the desired level of efficiency milestone, then the TeneoTwo shareholders have the possibility to receive payments up to USD 1.16 Billion.

 

  • In the month of February 2022, FDA granted the approval to ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc) which will be used in order to treat adult patients suffering with relapsed or with refractory multiple myeloma who have undergone four or more therapy procedures that includes an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and anti-CD38 monoclonal antibody.

 

  • In January 2021, In the EU, the antibody-drug combination trastuzumab deruxtecan has acquired conditional approval for use as a single agent in patients who are adults with unresectable or metastatic HER2-positive breast cancer who have previously undergone two or more HER2-based regimens.

 

  • In September 2020, AbbVie and I-Mab formed a strategic agreement to develop and market lemzoparlimab (also known as TJC4), a monoclonal antibody medication used to treat a variety of malignancies.

 

  • In March 2020, Gilead Sciences, a biopharmaceutical business located in the United States, has agreed to buy Forty Seven for $4.9 billion. With the inclusion of Forty Seven's exploratory lead product candidate, magrolimab, this purchase is expected to boost Gilead's immuno-oncology R&D portfolio. 

 

Frequently Asked Question About This Report

b: In the Regions segment, North America held the maximum share. Pharmaceutical and biotechnology companies have a wealth of experience and understanding in cancer monoclonal antibodies.

b: A total of 24 monoclonal antibodies (mAbs) targeting 16 distinct solid Tumor antigens have been authorised for the treatment of a growing variety of malignancies.

b: Cancer is treated with antibodies such as trastuzumab, pembrolizumab, and rituximab.

b: Monoclonal Antibodies (MABs) are a specific form of targeted pharmacological treatment. These medications are able to identify and locate certain proteins and kill cancer cells.

b: Therapeutic monoclonal antibodies have been gaining popularity year after year. Their very specific antigen targeting can give very effective medical therapy, and molecular-targeted medicine is permitting the overall development of the new generation of therapeutic medicines.

b: North America has the highest growth rate.

b: Amgen Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Genmab AS, GlaxoSmithKline PLC, Eli Lilly and Company, Novartis AG, Johnson & Johnson, Seattle Genetics Inc., and Spectrum Pharmaceuticals Inc. few among others, are the most promising players who are operating in the global market.

b: The global cancer monoclonal antibodies market size was $51.88 Billion in 2021. It is estimated to reach $108.47 Billion by 2030, representing a CAGR of 8.54% throughout the forecasted period of 2021-2030.

b: The global market size in 2021 was around USD 51.88 Billion and it is expected to expand at an 8.54% CAGR from 2020 to 2030. As a result, the Global market Forecast suggests reaching around USD 108.47 Billion by 2030.

.